In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Trinity gains bioMerieux blood coagulation testing line

This article was originally published in The Gray Sheet

Executive Summary

Automated instruments and reagent menu for blood clotting parameter analysis composing bioMerieux's hemostasis product line are acquired by diagnostics firm Trinity Biotech May 25. Trinity will pay up to $51.9 mil., including $40 mil. at closing, with deferred payments of up to $11.9 mil. over two years. Combining the bioMerieux line with Trinity's existing coagulation testing products will add $40 mil. to Trinity's revenue next year and boost its share of the $600 mil. worldwide coagulation testing market from its current 5% level to an estimated 13%, the firm says. The market is growing at about 5% annually. The deal is in line with bioMerieux' focus on infectious diseases, cancer and cardiovascular diseases...

You may also be interested in...



BioMérieux Moves Forward With HPV, Sepsis Diagnostic Agreements

BioMérieux announced two deals last week as part of its five-year strategic plan focusing on infectious diseases and personalized diagnostics

Abbott Launches Five-Minute POC Rapid COVID-19 Test

Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.

In A Bizarre Move, Trump Orders GM To Make Ventilators – Even Though The Auto Giant Already Is

President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.

UsernamePublicRestriction

Register

MT023607

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel